{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:28:33Z","timestamp":1749061713429},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Acute graft-versus-host disease (aGVHD) is one of the most common causes of morbidity for patients undergoing allogeneic stem cell transplantation. There is preliminary evidence that activated Group 2 innate lymphoid cells (ILC2s) from wild type (WT) mice reduces the lethality of aGVHD and is effective in treating lower gastrointestinal (GI) tract manifestations of aGVHD. This raises the prospect that ILC2s may be used for cell-based therapy of aGVHD but vigorous investigation is necessary to assess their impacts on different aspects of aGVHD. Genetically engineered mice which either express Id1 protein (Id1<jats:sup>tg\/tg<\/jats:sup>), an inhibitor of E protein transcription factors or have E protein genes knocked out (dKO) in the thymus produce massive numbers of ILC2s, thus allowing extensive evaluation of ILC2s. We investigated whether these ILC2s have protective effects in aGVHD as WT ILC2s do using an established mouse model of aGVHD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>bone marrow transplant was performed by irradiating BALB\/c strain of recipient mice and transplanting with bone marrow and T cells from the MHC-disparate C57BL\/6 strain. We isolated ILC2s from Id1<jats:sup>tg\/tg<\/jats:sup> and dKO mice and co-transplanted them to study their effects. Our results confirm that activated ILC2s have a protective role in aGVHD, but the effects varied depending on the origin of ILC2s. Co-transplantation of ILC2s from Id1<jats:sup>tg\/tg<\/jats:sup> mice were beneficial in aGVHD and are especially helpful in ameliorating the skin manifestations of aGVHD. However, ILC2s from dKO mice were less effective at the protection and behaved differently depending on if the cells were isolated from dKO mice were pre-treated with IL-25 in vivo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These findings support the notion that thymus-derived ILC2s from Id1<jats:sup>tg\/tg<\/jats:sup> mice are protective against aGVHD, with a significant improvement of skin lesions and they behave differently from dKO mice in the setting of aGVHD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12865-021-00432-w","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T23:06:32Z","timestamp":1626217592000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Type 2 innate lymphoid cells from Id1 transgenic mice alleviate skin manifestations of graft-versus-host disease"],"prefix":"10.1186","volume":"22","author":[{"given":"Anand","family":"Srinivasan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Bajana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneta","family":"Pankow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikin K.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Hong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"issue":"10","key":"432_CR1","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1182\/blood.2020005590","volume":"136","author":"R Chiesa","year":"2020","unstructured":"Chiesa R, Wang J, Blok HJ, Hazelaar S, Neven B, Moshous D, et al. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. Blood. 2020;136(10):1201\u201311. https:\/\/doi.org\/10.1182\/blood.2020005590.","journal-title":"Blood"},{"issue":"10","key":"432_CR2","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","volume":"54","author":"RF Duarte","year":"2019","unstructured":"Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019;54(10):1525\u201352. https:\/\/doi.org\/10.1038\/s41409-019-0516-2.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"432_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/MOH.0000000000000281","volume":"23","author":"GE Georges","year":"2016","unstructured":"Georges GE, Storb R. Hematopoietic stem cell transplantation for acquired aplastic anemia. Curr Opin Hematol. 2016;23(6):495\u2013500. https:\/\/doi.org\/10.1097\/MOH.0000000000000281.","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"432_CR4","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/MOH.0000000000000282","volume":"23","author":"TM Robinson","year":"2016","unstructured":"Robinson TM, Fuchs EJ. Allogeneic stem cell transplantation for sickle cell disease. Curr Opin Hematol. 2016;23(6):524\u20139. https:\/\/doi.org\/10.1097\/MOH.0000000000000282.","journal-title":"Curr Opin Hematol"},{"issue":"22","key":"432_CR5","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167\u201379. https:\/\/doi.org\/10.1056\/NEJMra1609337.","journal-title":"N Engl J Med"},{"issue":"9674","key":"432_CR6","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","volume":"373","author":"JL Ferrara","year":"2009","unstructured":"Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(09)60237-3.","journal-title":"Lancet"},{"key":"432_CR7","doi-asserted-by":"crossref","unstructured":"Holler E, Greinix H, Zeiser R: Acute Graft-Versus-Host Disease 2019:323\u2013330.","DOI":"10.1007\/978-3-030-02278-5_43"},{"issue":"5","key":"432_CR8","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","volume":"174","author":"E Vivier","year":"2018","unstructured":"Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells: 10 years on. Cell. 2018;174(5):1054\u201366. https:\/\/doi.org\/10.1016\/j.cell.2018.07.017.","journal-title":"Cell"},{"issue":"7534","key":"432_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nature14189","volume":"517","author":"D Artis","year":"2015","unstructured":"Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517(7534):293\u2013301. https:\/\/doi.org\/10.1038\/nature14189.","journal-title":"Nature"},{"issue":"8","key":"432_CR10","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/eji.201747388","volume":"48","author":"S Cording","year":"2018","unstructured":"Cording S, Medvedovic J, Lecuyer E, Aychek T, Dejardin F, Eberl G. Mouse models for the study of fate and function of innate lymphoid cells. Eur J Immunol. 2018;48(8):1271\u201380. https:\/\/doi.org\/10.1002\/eji.201747388.","journal-title":"Eur J Immunol"},{"issue":"11","key":"432_CR11","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/ni.2131","volume":"12","author":"LA Monticelli","year":"2011","unstructured":"Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG, Doering TA, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol. 2011;12(11):1045\u201354. https:\/\/doi.org\/10.1038\/ni.2131.","journal-title":"Nat Immunol"},{"issue":"7","key":"432_CR12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ni.3489","volume":"17","author":"CS Klose","year":"2016","unstructured":"Klose CS, Artis D. Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat Immunol. 2016;17(7):765\u201374. https:\/\/doi.org\/10.1038\/ni.3489.","journal-title":"Nat Immunol"},{"issue":"5","key":"432_CR13","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2013-11-536888","volume":"124","author":"JM Munneke","year":"2014","unstructured":"Munneke JM, Bjorklund AT, Mjosberg JM, Garming-Legert K, Bernink JH, Blom B, et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. Blood. 2014;124(5):812\u201321. https:\/\/doi.org\/10.1182\/blood-2013-11-536888.","journal-title":"Blood"},{"issue":"5","key":"432_CR14","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1172\/JCI91816","volume":"127","author":"DW Bruce","year":"2017","unstructured":"Bruce DW, Stefanski HE, Vincent BG, Dant TA, Reisdorf S, Bommiasamy H, et al. Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease. J Clin Invest. 2017;127(5):1813\u201325. https:\/\/doi.org\/10.1172\/JCI91816.","journal-title":"J Clin Invest"},{"issue":"7496","key":"432_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nature13047","volume":"508","author":"MG Constantinides","year":"2014","unstructured":"Constantinides MG, McDonald BD, Verhoef PA, Bendelac A. A committed precursor to innate lymphoid cells. Nature. 2014;508(7496):397\u2013401. https:\/\/doi.org\/10.1038\/nature13047.","journal-title":"Nature"},{"key":"432_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.coi.2016.01.006","volume":"39","author":"Q Yang","year":"2016","unstructured":"Yang Q, Bhandoola A. The development of adult innate lymphoid cells. Curr Opin Immunol. 2016;39:114\u201320. https:\/\/doi.org\/10.1016\/j.coi.2016.01.006.","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"432_CR17","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/ni.3481","volume":"17","author":"EC Zook","year":"2016","unstructured":"Zook EC, Kee BL. Development of innate lymphoid cells. Nat Immunol. 2016;17(7):775\u201382. https:\/\/doi.org\/10.1038\/ni.3481.","journal-title":"Nat Immunol"},{"issue":"8","key":"432_CR18","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.4049\/jimmunol.1602009","volume":"198","author":"HC Wang","year":"2017","unstructured":"Wang HC, Qian L, Zhao Y, Mengarelli J, Adrianto I, Montgomery CG, et al. Downregulation of E protein activity augments an ILC2 differentiation program in the Thymus. J Immunol. 2017;198(8):3149\u201356. https:\/\/doi.org\/10.4049\/jimmunol.1602009.","journal-title":"J Immunol"},{"issue":"4","key":"432_CR19","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1084\/jem.20182100","volume":"216","author":"L Qian","year":"2019","unstructured":"Qian L, Bajana S, Georgescu C, Peng V, Wang HC, Adrianto I, et al. Suppression of ILC2 differentiation from committed T cell precursors by E protein transcription factors. J Exp Med. 2019;216(4):884\u201399. https:\/\/doi.org\/10.1084\/jem.20182100.","journal-title":"J Exp Med"},{"issue":"5","key":"432_CR20","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.immuni.2017.04.022","volume":"46","author":"M Miyazaki","year":"2017","unstructured":"Miyazaki M, Miyazaki K, Chen K, Jin Y, Turner J, Moore AJ, et al. The E-id protein Axis specifies adaptive lymphoid cell identity and suppresses Thymic innate lymphoid cell development. Immunity. 2017;46(5):818\u201334. https:\/\/doi.org\/10.1016\/j.immuni.2017.04.022.","journal-title":"Immunity"},{"issue":"5","key":"432_CR21","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/0092-8674(94)90078-7","volume":"79","author":"X-H Sun","year":"1994","unstructured":"Sun X-H. Constitutive expression of the Id1 gene impairs mouse B cell development. Cell. 1994;79(5):893\u2013900. https:\/\/doi.org\/10.1016\/0092-8674(94)90078-7.","journal-title":"Cell"},{"issue":"12","key":"432_CR22","doi-asserted-by":"publisher","first-page":"8240","DOI":"10.1128\/MCB.19.12.8240","volume":"19","author":"D Kim","year":"1999","unstructured":"Kim D, Peng XC, Sun XH. Massive apoptosis of thymocytes in T-cell-deficient Id1 transgenic mice. Mol Cell Biol. 1999;19(12):8240\u201353. https:\/\/doi.org\/10.1128\/MCB.19.12.8240.","journal-title":"Mol Cell Biol"},{"issue":"17","key":"432_CR23","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1128\/MCB.00119-09","volume":"29","author":"HC Wang","year":"2009","unstructured":"Wang HC, Perry SS, Sun XH. Id1 attenuates notch signaling and impairs T-cell commitment by elevating Deltex1 expression. Mol Cell Biol. 2009;29(17):4640\u201352. https:\/\/doi.org\/10.1128\/MCB.00119-09.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"432_CR24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1242\/dmm.006668","volume":"4","author":"MA Schroeder","year":"2011","unstructured":"Schroeder MA, DiPersio JF. Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech. 2011;4(3):318\u201333. https:\/\/doi.org\/10.1242\/dmm.006668.","journal-title":"Dis Model Mech"},{"issue":"2","key":"432_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/sj.bmt.1703328","volume":"29","author":"GA Van LL","year":"2002","unstructured":"Van LL GA, Atkinson K, Rainer SP, Sewell WA. A two-phase pathogenesis of graft-versus-host disease in mice. Bone Marrow Transplant. 2002;29(2):151\u20138. https:\/\/doi.org\/10.1038\/sj.bmt.1703328.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"432_CR26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.4049\/jimmunol.164.1.469","volume":"164","author":"MR van den Brink","year":"2000","unstructured":"van den Brink MR, Moore E, Horndasch KJ, Crawford JM, Hoffman J, Murphy GF, et al. Fas-deficient lpr mice are more susceptible to graft-versus-host disease. J Immunol. 2000;164(1):469\u201380. https:\/\/doi.org\/10.4049\/jimmunol.164.1.469.","journal-title":"J Immunol"},{"issue":"1","key":"432_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0092-8674(90)90214-Y","volume":"61","author":"R Benezra","year":"1990","unstructured":"Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. \u03a4he protein id: a negative regulator of helix-loop-helix DNA binding proteins. Cell. 1990;61(1):49\u201359. https:\/\/doi.org\/10.1016\/0092-8674(90)90214-Y.","journal-title":"Cell"},{"issue":"10","key":"432_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11882-017-0735-9","volume":"17","author":"L Cosmi","year":"2017","unstructured":"Cosmi L, Liotta F, Maggi L, Annunziato F. Role of type 2 innate lymphoid cells in allergic diseases. Curr Allergy Asthma Rep. 2017;17(10):66. https:\/\/doi.org\/10.1007\/s11882-017-0735-9.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"11","key":"432_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nri.2017.86","volume":"17","author":"M Ebbo","year":"2017","unstructured":"Ebbo M, Crinier A, Vely F, Vivier E. Innate lymphoid cells: major players in inflammatory diseases. Nat Rev Immunol. 2017;17(11):665\u201378. https:\/\/doi.org\/10.1038\/nri.2017.86.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"432_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00281-018-0670-4","volume":"40","author":"T Xiong","year":"2018","unstructured":"Xiong T, Turner JE. Innate lymphoid cells in autoimmunity and chronic inflammatory diseases. Semin Immunopathol. 2018;40(4):393\u2013406. https:\/\/doi.org\/10.1007\/s00281-018-0670-4.","journal-title":"Semin Immunopathol"},{"issue":"2","key":"432_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ni.3078","volume":"16","author":"Y Huang","year":"2015","unstructured":"Huang Y, Guo L, Qiu J, Chen X, Hu-Li J, Siebenlist U, et al. IL-25-responsive, lineage-negative KLRG1(hi) cells are multipotential 'inflammatory' type 2 innate lymphoid cells. Nat Immunol. 2015;16(2):161\u20139. https:\/\/doi.org\/10.1038\/ni.3078.","journal-title":"Nat Immunol"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-021-00432-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-021-00432-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-021-00432-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T23:28:51Z","timestamp":1626218931000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-021-00432-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["432"],"URL":"https:\/\/doi.org\/10.1186\/s12865-021-00432-w","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"assertion":[{"value":"24 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted after approval by the Institutional Animal Care and Use Committee (IACUC) as per international guidelines<b>.<\/b> All animal experiments were performed according to protocols approved by the Institutional Animal Care and Use Committee policies at the Oklahoma Medical Research Foundation. All animals were euthanized when they developed severe disease. All mice experiments comply with National Institutes of Health guidelines for the care and use of Laboratory animals and ARRIVE guidelines. No study on human subjects is involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no specific conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}